English

Spark Therapeutics, Inc.

EDGAR

ONCE Current report (8-K) · filed 2019-12-17

45 filing records in this dataset, filed from 2014-12-30 to 2019-12-17. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

22.4 million USD

2019 Q3 · USD

Exact inputs and evidence

Revenue: 22447000 USD Source

Operating margin

-305.87%

2019 Q3 · %

Exact inputs and evidence

Operating Income: -68658000 USD Source
Revenue: 22447000 USD Source

Operating cash flow

-18.4 million USD

2019 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -100448000 USD Source
Operating Cash Flow: -82073000 USD Source

Free cash flow

-25.8 million USD

2019 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -100448000 USD Source
Operating Cash Flow: -82073000 USD Source
Capital Expenditure: 17677000 USD Source
Capital Expenditure: 10233000 USD Source

Cash and cash equivalents: 207 million USD 2019-09-30 Source
Exact value

207137000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 38.5 million shares 2019-09-30 Source
Exact value

38519183 shares

Reported share-count change

2.42% · 909 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

37610295 shares · 2018-09-30· Source
38519183 shares · 2019-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

69.9 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Revenue: 13157000 USD · 2018-10-01 – 2018-12-31 Source
Revenue: 20771000 USD · 2019-01-01 – 2019-03-31 Source
Revenue: 13503000 USD · 2019-04-01 – 2019-06-30 Source
Revenue: 22447000 USD · 2019-07-01 – 2019-09-30 Source

Net income

-250 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Net income: -65257000 USD · 2018-10-01 – 2018-12-31 Source
Net income: -54358000 USD · 2019-01-01 – 2019-03-31 Source
Net income: -64230000 USD · 2019-04-01 – 2019-06-30 Source
Net income: -66602000 USD · 2019-07-01 – 2019-09-30 Source

Operating cash flow

-143 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Operating cash flow: -70563000 USD · 2018-01-01 – 2018-12-31 Source
Operating cash flow: -28036000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -32099000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -82073000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -32099000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -100448000 USD · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -82073000 USD · 2019-01-01 – 2019-06-30 Source

Capital expenditure

36.6 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Capital expenditure: 33821000 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 14920000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 4288000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 10233000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 4288000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 17677000 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 10233000 USD · 2019-01-01 – 2019-06-30 Source

Free cash flow

-180 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Operating cash flow: -70563000 USD · 2018-01-01 – 2018-12-31 Source
Operating cash flow: -28036000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -32099000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -82073000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -32099000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -100448000 USD · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -82073000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 33821000 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 14920000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 4288000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 10233000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 4288000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 17677000 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 10233000 USD · 2019-01-01 – 2019-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2019-12-17.

Financial data available through: 2018-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2018-12-31
Operating income: 5 of 11 periods available· newest 2018-12-31
Net income: 5 of 11 periods available· newest 2018-12-31
Operating cash flow: 5 of 11 periods available· newest 2018-12-31
Capital expenditure: 5 of 11 periods available· newest 2018-12-31
Total assets: 5 of 11 periods available· newest 2018-12-31
Total liabilities: 5 of 11 periods available· newest 2018-12-31
Current assets: 5 of 11 periods available· newest 2018-12-31
Current liabilities: 5 of 11 periods available· newest 2018-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2018-12-31
long term debt: No compatible figures in this window
Shares outstanding: 5 of 11 periods available· newest 2018-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+436.4%

Prior period

USD 12.07 million

2017-01-01 – 2017-12-31
Current period

USD 64.73 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

64725000 − 12066000 = 52659000 USD

12066000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
64725000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Spark Therapeutics, Inc. · 2018-12-31 Spark Therapeutics, Inc. (edgar:1609351) Year-over-year change in Revenue: 52659000 USD Concept: fundies:Revenue Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 64725000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#1820036 Filing: 000160935119000042 Input fundies:Revenue: 12066000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#1819176 Filing: 000160935119000042
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 174.66 million

Prior period

−USD 253.48 million

2017-01-01 – 2017-12-31
Current period

−USD 78.82 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

-78822000 − -253482000 = 174660000 USD

-253482000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
-78822000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Spark Therapeutics, Inc. · 2018-12-31 Spark Therapeutics, Inc. (edgar:1609351) Year-over-year change in Net income: 174660000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -78822000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2162369 Filing: 000160935119000042 Input fundies:NetIncome: -253482000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2161322 Filing: 000160935119000042
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 83.97 million

Prior period

−USD 154.54 million

2017-01-01 – 2017-12-31
Current period

−USD 70.56 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

-70563000 − -154536000 = 83973000 USD

-154536000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
-70563000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Spark Therapeutics, Inc. · 2018-12-31 Spark Therapeutics, Inc. (edgar:1609351) Year-over-year change in Operating cash flow: 83973000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -70563000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2214502 Filing: 000160935119000042 Input fundies:OperatingCashFlow: -154536000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2213473 Filing: 000160935119000042
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+250.3%

Prior period

USD 9.65 million

2017-01-01 – 2017-12-31
Current period

USD 33.82 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

33821000 − 9654000 = 24167000 USD

9654000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
33821000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Spark Therapeutics, Inc. · 2018-12-31 Spark Therapeutics, Inc. (edgar:1609351) Year-over-year change in Capital expenditure: 24167000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 33821000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2235590 Filing: 000160935119000042 Input fundies:CapitalExpenditure: 9654000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2234630 Filing: 000160935119000042
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2018 2018-01-01 – 2018-12-31

Revenue USD 64.73 million 100% of revenue
Operating costs Derived USD 258.36 million 399% of revenue
Operating income −USD 193.64 million −299% of revenue
Tax, interest and other Derived −USD 114.82 million −177% of revenue
Net income −USD 78.82 million −122% of revenue

Cash

Operating cash flow −USD 70.56 million −109% of revenue
Capital expenditure USD 33.82 million 52% of revenue
Free cash flow Derived −USD 104.38 million −161% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Operating loss: operating costs were 3,938% of revenue.
2015 Operating loss: operating costs were 314% of revenue.
2016 Operating loss: operating costs were 721% of revenue.
2017 Operating loss: operating costs were 2,243% of revenue.
2018 Operating loss: operating costs were 399% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	633932	24964261 Derived	-24330329	-5520 Derived	-24324809	-1310583 Derived	Source 2014-01-01 – 2014-12-31: 633932 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -24330329 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -24324809 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: 10386379 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 11696962 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	22063674	69381485 Derived	-47317811	-192033 Derived	-47125778	-51999996 Derived	Source 2015-01-01 – 2015-12-31: 22063674 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -47317811 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -47125778 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -47478227 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 4521769 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	20183000	145582000 Derived	-125399000	-1746000 Derived	-123653000	-88974000 Derived	Source 2016-01-01 – 2016-12-31: 20183000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -125399000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -123653000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -80442000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 8532000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	12066000	270584000 Derived	-258518000	-5036000 Derived	-253482000	-164190000 Derived	Source 2017-01-01 – 2017-12-31: 12066000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -258518000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -253482000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -154536000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 9654000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	64725000	258364000 Derived	-193639000	-114817000 Derived	-78822000	-104384000 Derived	Source 2018-01-01 – 2018-12-31: 64725000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -193639000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -78822000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -70563000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 33821000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 64.7M 2018

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	633932	Revenue: 633932 Open source
20152015-12-31	Revenue	22063674	Revenue: 22063674 Open source
20162016-12-31	Revenue	20183000	Revenue: 20183000 Open source
20172017-12-31	Revenue	12066000	Revenue: 12066000 Open source
20182018-12-31	Revenue	64725000	Revenue: 64725000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

436.4% 2018

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 633932 Open source
20152015-12-31	Year over year	3,380.4%	Revenue: 22063674 Open source Revenue: 633932 Open source
20162016-12-31	Year over year	-8.5%	Revenue: 20183000 Open source Revenue: 22063674 Open source
20172017-12-31	Year over year	-40.2%	Revenue: 12066000 Open source Revenue: 20183000 Open source
20182018-12-31	Year over year	436.4%	Revenue: 64725000 Open source Revenue: 12066000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -299.2% 2018

Net margin -121.8% 2018

Free cash flow margin -161.3% 2018

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	-3,838%	Operating Income: -24330329 Open source Revenue: 633932 Open source
20152015-12-31	Operating margin	-214.5%	Operating Income: -47317811 Open source Revenue: 22063674 Open source
20162016-12-31	Operating margin	-621.3%	Operating Income: -125399000 Open source Revenue: 20183000 Open source
20172017-12-31	Operating margin	-2,142.5%	Operating Income: -258518000 Open source Revenue: 12066000 Open source
20182018-12-31	Operating margin	-299.2%	Operating Income: -193639000 Open source Revenue: 64725000 Open source
20142014-12-31	Net margin	-3,837.1%	Net Income: -24324809 Open source Revenue: 633932 Open source
20152015-12-31	Net margin	-213.6%	Net Income: -47125778 Open source Revenue: 22063674 Open source
20162016-12-31	Net margin	-612.7%	Net Income: -123653000 Open source Revenue: 20183000 Open source
20172017-12-31	Net margin	-2,100.8%	Net Income: -253482000 Open source Revenue: 12066000 Open source
20182018-12-31	Net margin	-121.8%	Net Income: -78822000 Open source Revenue: 64725000 Open source
20142014-12-31	Free cash flow margin	-206.7%	Revenue: 633932 Open source Operating Cash Flow: 10386379 Open source Capital Expenditure: 11696962 Open source
20152015-12-31	Free cash flow margin	-235.7%	Revenue: 22063674 Open source Operating Cash Flow: -47478227 Open source Capital Expenditure: 4521769 Open source
20162016-12-31	Free cash flow margin	-440.8%	Revenue: 20183000 Open source Operating Cash Flow: -80442000 Open source Capital Expenditure: 8532000 Open source
20172017-12-31	Free cash flow margin	-1,360.8%	Revenue: 12066000 Open source Operating Cash Flow: -154536000 Open source Capital Expenditure: 9654000 Open source
20182018-12-31	Free cash flow margin	-161.3%	Revenue: 64725000 Open source Operating Cash Flow: -70563000 Open source Capital Expenditure: 33821000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -70.6M 2018

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	10386379	Operating Cash Flow: 10386379 Open source
20152015-12-31	Operating cash flow	-47478227	Operating Cash Flow: -47478227 Open source
20162016-12-31	Operating cash flow	-80442000	Operating Cash Flow: -80442000 Open source
20172017-12-31	Operating cash flow	-154536000	Operating Cash Flow: -154536000 Open source
20182018-12-31	Operating cash flow	-70563000	Operating Cash Flow: -70563000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -104.4M 2018

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	-1310583	Operating Cash Flow: 10386379 Open source Capital Expenditure: 11696962 Open source
20152015-12-31	Free cash flow	-51999996	Operating Cash Flow: -47478227 Open source Capital Expenditure: 4521769 Open source
20162016-12-31	Free cash flow	-88974000	Operating Cash Flow: -80442000 Open source Capital Expenditure: 8532000 Open source
20172017-12-31	Free cash flow	-164190000	Operating Cash Flow: -154536000 Open source Capital Expenditure: 9654000 Open source
20182018-12-31	Free cash flow	-104384000	Operating Cash Flow: -70563000 Open source Capital Expenditure: 33821000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

39% 2018

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Liabilities / assets	39%	Total Liabilities: 35240131 Open source Total Assets: 90445851 Open source
20152015-12-31	Liabilities / assets	11.9%	Total Liabilities: 39234719 Open source Total Assets: 329772514 Open source
20162016-12-31	Liabilities / assets	11.7%	Total Liabilities: 43586082 Open source Total Assets: 373862795 Open source
20172017-12-31	Liabilities / assets	16.7%	Total Liabilities: 103172000 Open source Total Assets: 616796000 Open source
20182018-12-31	Liabilities / assets	39%	Total Liabilities: 317839000 Open source Total Assets: 814352000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

9.1× 2018

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Current assets / current liabilities	4.88×	Current Assets: 77363268 Open source Current Liabilities: 15854228 Open source
20152015-12-31	Current assets / current liabilities	14.09×	Current Assets: 311607784 Open source Current Liabilities: 22115651 Open source
20162016-12-31	Current assets / current liabilities	10.49×	Current Assets: 314593677 Open source Current Liabilities: 29997540 Open source
20172017-12-31	Current assets / current liabilities	9.93×	Current Assets: 533166000 Open source Current Liabilities: 53687000 Open source
20182018-12-31	Current assets / current liabilities	9.1×	Current Assets: 567140000 Open source Current Liabilities: 62354000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 24.32 million Exact value Exact value: -24324809 USD 2014-01-01 – 2014-12-31: -24324809 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spark Therapeutics, Inc. · 2014-12-31 Spark Therapeutics, Inc. (edgar:1609351) Net Income: -24324809 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -24324809 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935117000017/once-20161231.xml#236581 Filing: 000160935117000017 The citation records this snapshot. The page link may show a newer release later.	USD 10.39 million Exact value Exact value: 10386379 USD 2014-01-01 – 2014-12-31: 10386379 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spark Therapeutics, Inc. · 2014-12-31 Spark Therapeutics, Inc. (edgar:1609351) Operating Cash Flow: 10386379 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 10386379 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935117000017/once-20161231.xml#235829 Filing: 000160935117000017 The citation records this snapshot. The page link may show a newer release later.	USD 11.7 million Exact value Exact value: 11696962 USD 2014-01-01 – 2014-12-31: 11696962 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spark Therapeutics, Inc. · 2014-12-31 Spark Therapeutics, Inc. (edgar:1609351) Capital Expenditure: 11696962 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11696962 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935117000017/once-20161231.xml#255601 Filing: 000160935117000017 The citation records this snapshot. The page link may show a newer release later.	−USD 1.31 million Calculation and evidence 10386379 − 11696962 USD Exact free cash flow: -1310583 USD 2014-01-01 – 2014-12-31: 10386379 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 11696962 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spark Therapeutics, Inc. · 2014-12-31 Spark Therapeutics, Inc. (edgar:1609351) Free cash flow: -1310583 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 10386379 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935117000017/once-20161231.xml#235829 Filing: 000160935117000017 Input fundies:CapitalExpenditure: 11696962 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935117000017/once-20161231.xml#255601 Filing: 000160935117000017 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 47.13 million Exact value Exact value: -47125778 USD 2015-01-01 – 2015-12-31: -47125778 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spark Therapeutics, Inc. · 2015-12-31 Spark Therapeutics, Inc. (edgar:1609351) Net Income: -47125778 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -47125778 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935118000026/once-20171231.xml#251185 Filing: 000160935118000026 The citation records this snapshot. The page link may show a newer release later.	−USD 47.48 million Exact value Exact value: -47478227 USD 2015-01-01 – 2015-12-31: -47478227 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spark Therapeutics, Inc. · 2015-12-31 Spark Therapeutics, Inc. (edgar:1609351) Operating Cash Flow: -47478227 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -47478227 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935118000026/once-20171231.xml#250431 Filing: 000160935118000026 The citation records this snapshot. The page link may show a newer release later.	USD 4.52 million Exact value Exact value: 4521769 USD 2015-01-01 – 2015-12-31: 4521769 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spark Therapeutics, Inc. · 2015-12-31 Spark Therapeutics, Inc. (edgar:1609351) Capital Expenditure: 4521769 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4521769 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935118000026/once-20171231.xml#276528 Filing: 000160935118000026 The citation records this snapshot. The page link may show a newer release later.	−USD 52 million Calculation and evidence -47478227 − 4521769 USD Exact free cash flow: -51999996 USD 2015-01-01 – 2015-12-31: -47478227 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 4521769 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spark Therapeutics, Inc. · 2015-12-31 Spark Therapeutics, Inc. (edgar:1609351) Free cash flow: -51999996 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -47478227 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935118000026/once-20171231.xml#250431 Filing: 000160935118000026 Input fundies:CapitalExpenditure: 4521769 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935118000026/once-20171231.xml#276528 Filing: 000160935118000026 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 123.65 million Exact value Exact value: -123653000 USD 2016-01-01 – 2016-12-31: -123653000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spark Therapeutics, Inc. · 2016-12-31 Spark Therapeutics, Inc. (edgar:1609351) Net Income: -123653000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -123653000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2160275 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.	−USD 80.44 million Exact value Exact value: -80442000 USD 2016-01-01 – 2016-12-31: -80442000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spark Therapeutics, Inc. · 2016-12-31 Spark Therapeutics, Inc. (edgar:1609351) Operating Cash Flow: -80442000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -80442000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2212474 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.	USD 8.53 million Exact value Exact value: 8532000 USD 2016-01-01 – 2016-12-31: 8532000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spark Therapeutics, Inc. · 2016-12-31 Spark Therapeutics, Inc. (edgar:1609351) Capital Expenditure: 8532000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8532000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2233670 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.	−USD 88.97 million Calculation and evidence -80442000 − 8532000 USD Exact free cash flow: -88974000 USD 2016-01-01 – 2016-12-31: -80442000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 8532000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spark Therapeutics, Inc. · 2016-12-31 Spark Therapeutics, Inc. (edgar:1609351) Free cash flow: -88974000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -80442000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2212474 Filing: 000160935119000042 Input fundies:CapitalExpenditure: 8532000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2233670 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 253.48 million Exact value Exact value: -253482000 USD 2017-01-01 – 2017-12-31: -253482000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spark Therapeutics, Inc. · 2017-12-31 Spark Therapeutics, Inc. (edgar:1609351) Net Income: -253482000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -253482000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2161322 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.	−USD 154.54 million Exact value Exact value: -154536000 USD 2017-01-01 – 2017-12-31: -154536000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spark Therapeutics, Inc. · 2017-12-31 Spark Therapeutics, Inc. (edgar:1609351) Operating Cash Flow: -154536000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -154536000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2213473 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.	USD 9.65 million Exact value Exact value: 9654000 USD 2017-01-01 – 2017-12-31: 9654000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spark Therapeutics, Inc. · 2017-12-31 Spark Therapeutics, Inc. (edgar:1609351) Capital Expenditure: 9654000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9654000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2234630 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.	−USD 164.19 million Calculation and evidence -154536000 − 9654000 USD Exact free cash flow: -164190000 USD 2017-01-01 – 2017-12-31: -154536000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 9654000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spark Therapeutics, Inc. · 2017-12-31 Spark Therapeutics, Inc. (edgar:1609351) Free cash flow: -164190000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -154536000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2213473 Filing: 000160935119000042 Input fundies:CapitalExpenditure: 9654000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2234630 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 78.82 million Exact value Exact value: -78822000 USD 2018-01-01 – 2018-12-31: -78822000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Spark Therapeutics, Inc. · 2018-12-31 Spark Therapeutics, Inc. (edgar:1609351) Net Income: -78822000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -78822000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2162369 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.	−USD 70.56 million Exact value Exact value: -70563000 USD 2018-01-01 – 2018-12-31: -70563000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Spark Therapeutics, Inc. · 2018-12-31 Spark Therapeutics, Inc. (edgar:1609351) Operating Cash Flow: -70563000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70563000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2214502 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.	USD 33.82 million Exact value Exact value: 33821000 USD 2018-01-01 – 2018-12-31: 33821000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Spark Therapeutics, Inc. · 2018-12-31 Spark Therapeutics, Inc. (edgar:1609351) Capital Expenditure: 33821000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 33821000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2235590 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.	−USD 104.38 million Calculation and evidence -70563000 − 33821000 USD Exact free cash flow: -104384000 USD 2018-01-01 – 2018-12-31: -70563000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 33821000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Spark Therapeutics, Inc. · 2018-12-31 Spark Therapeutics, Inc. (edgar:1609351) Free cash flow: -104384000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T13:38:23Z Snapshot: 29919b1fecae4b4e39290fcafd8da8cdb660313c8304ae80e4d2be729f4a4589 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1609351?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70563000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2214502 Filing: 000160935119000042 Input fundies:CapitalExpenditure: 33821000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1609351/000160935119000042/spark-201810xk.htm#2235590 Filing: 000160935119000042 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

45 filings · 1,544 latest values · 1,544 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001609351, 1609351, ONCE, edgar:1609351

Also known as Spark Therapeutics, Inc.

Spark Therapeutics, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2018 2018-01-01 – 2018-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation